DXB Stock Overview
A biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Dimerix Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.32 |
| 52 Week High | AU$0.67 |
| 52 Week Low | AU$0.16 |
| Beta | 0.52 |
| 1 Month Change | -5.97% |
| 3 Month Change | -12.50% |
| 1 Year Change | 75.00% |
| 3 Year Change | 28.57% |
| 5 Year Change | 142.31% |
| Change since IPO | 57.50% |
Recent News & Updates
Recent updates
We're Interested To See How Dimerix (ASX:DXB) Uses Its Cash Hoard To Grow
Dec 20
Is Dimerix (ASX:DXB) Using Too Much Debt?
Dec 19We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate
Jul 05Can Dimerix (ASX:DXB) Afford To Invest In Growth?
Feb 17We're A Little Worried About Dimerix's (ASX:DXB) Cash Burn Rate
Sep 16We're Keeping An Eye On Dimerix's (ASX:DXB) Cash Burn Rate
Jun 02Most Shareholders Will Probably Agree With Dimerix Limited's (ASX:DXB) CEO Compensation
Sep 20Is Dimerix (ASX:DXB) In A Good Position To Deliver On Growth Plans?
May 17Here's What We Think About Dimerix's (ASX:DXB) CEO Pay
Feb 01Shareholder Returns
| DXB | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -10.0% | 1.5% | -2.0% |
| 1Y | 75.0% | 4.3% | 7.8% |
Return vs Industry: DXB exceeded the Australian Biotechs industry which returned 4.3% over the past year.
Return vs Market: DXB exceeded the Australian Market which returned 7.8% over the past year.
Price Volatility
| DXB volatility | |
|---|---|
| DXB Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 9.4% |
| Market Average Movement | 8.0% |
| 10% most volatile stocks in AU Market | 16.8% |
| 10% least volatile stocks in AU Market | 3.1% |
Stable Share Price: DXB has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: DXB's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Nina Webster | dimerix.com |
Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs in Australia. The company develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 which is in phase 2 clinical trial for diabetic kidney disease; DMX-200 for ARDS associated with COVID-19; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. Dimerix Limited is headquartered in Fitzroy, Australia.
Dimerix Limited Fundamentals Summary
| DXB fundamental statistics | |
|---|---|
| Market cap | AU$175.72m |
| Earnings (TTM) | -AU$17.08m |
| Revenue (TTM) | AU$583.48k |
301.2x
P/S Ratio-10.3x
P/E RatioIs DXB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DXB income statement (TTM) | |
|---|---|
| Revenue | AU$583.48k |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$583.48k |
| Other Expenses | AU$17.66m |
| Earnings | -AU$17.08m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.031 |
| Gross Margin | 100.00% |
| Net Profit Margin | -2,926.43% |
| Debt/Equity Ratio | 0% |
How did DXB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 20:35 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dimerix Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|